UY39900A - Anticuerpos anti-vegfr1 y sus usos - Google Patents

Anticuerpos anti-vegfr1 y sus usos

Info

Publication number
UY39900A
UY39900A UY0001039900A UY39900A UY39900A UY 39900 A UY39900 A UY 39900A UY 0001039900 A UY0001039900 A UY 0001039900A UY 39900 A UY39900 A UY 39900A UY 39900 A UY39900 A UY 39900A
Authority
UY
Uruguay
Prior art keywords
vegfr1
antibodies
vegfr1 antibodies
polynucleotides
antigen
Prior art date
Application number
UY0001039900A
Other languages
English (en)
Spanish (es)
Inventor
Songmao Zheng
D Breyer Matthew
A Gonzalez Villalobos Romer
Jigjun Li
J Rutkoski Thomas
V Swanson Ronald
Gang Zheng
Xirong Zheng
Original Assignee
Janssen Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Biotech Inc filed Critical Janssen Biotech Inc
Publication of UY39900A publication Critical patent/UY39900A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
UY0001039900A 2021-08-16 2022-08-15 Anticuerpos anti-vegfr1 y sus usos UY39900A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163233343P 2021-08-16 2021-08-16
US202263322273P 2022-03-22 2022-03-22

Publications (1)

Publication Number Publication Date
UY39900A true UY39900A (es) 2023-02-28

Family

ID=85239767

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001039900A UY39900A (es) 2021-08-16 2022-08-15 Anticuerpos anti-vegfr1 y sus usos

Country Status (14)

Country Link
US (1) US20240425603A1 (cg-RX-API-DMAC7.html)
EP (1) EP4388011A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024534034A (cg-RX-API-DMAC7.html)
KR (1) KR20240046239A (cg-RX-API-DMAC7.html)
CN (1) CN119285771A (cg-RX-API-DMAC7.html)
AU (1) AU2022331414A1 (cg-RX-API-DMAC7.html)
CA (1) CA3229430A1 (cg-RX-API-DMAC7.html)
CL (1) CL2024000445A1 (cg-RX-API-DMAC7.html)
CO (1) CO2024001686A2 (cg-RX-API-DMAC7.html)
IL (1) IL310840A (cg-RX-API-DMAC7.html)
MX (1) MX2024002112A (cg-RX-API-DMAC7.html)
TW (1) TW202315888A (cg-RX-API-DMAC7.html)
UY (1) UY39900A (cg-RX-API-DMAC7.html)
WO (1) WO2023023465A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20260051101A (ko) * 2023-04-26 2026-04-15 사이즈믹 테라퓨틱, 인코포레이티드. 면역 체계를 조절하는 분자 및 그 용도
WO2026072909A2 (en) * 2024-09-27 2026-04-02 Amgen Inc. Flt1 binding proteins and methods of use

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013176366A (ja) * 2012-02-28 2013-09-09 Oncotherapy Science Ltd Vegfr1由来ペプチドおよびそれを含むワクチン
JO3519B1 (ar) * 2013-01-25 2020-07-05 Amgen Inc تركيبات أجسام مضادة لأجل cdh19 و cd3
TW201517916A (zh) * 2013-03-15 2015-05-16 Lilly Co Eli Vegfr1抗體之治療用途
US10738123B2 (en) * 2015-04-07 2020-08-11 Shire Human Genetic Therapies, Inc. Anti-FLT-1 antibodies in treating bronchopulmonary dysplasia
EP3993832A4 (en) * 2019-07-03 2023-10-18 Crystal Bioscience Inc. ANTI-CD38 ANTIBODIES AND METHOD OF USE THEREOF
CN110452297B (zh) * 2019-09-03 2020-04-14 上海洛启生物医药技术有限公司 抗vegf单域抗体及其应用

Also Published As

Publication number Publication date
WO2023023465A1 (en) 2023-02-23
KR20240046239A (ko) 2024-04-08
MX2024002112A (es) 2024-05-03
AU2022331414A1 (en) 2024-04-04
JP2024534034A (ja) 2024-09-18
CO2024001686A2 (es) 2024-02-26
US20240425603A1 (en) 2024-12-26
CL2024000445A1 (es) 2024-08-23
EP4388011A4 (en) 2025-07-30
EP4388011A1 (en) 2024-06-26
TW202315888A (zh) 2023-04-16
CN119285771A (zh) 2025-01-10
CA3229430A1 (en) 2023-02-23
IL310840A (en) 2024-04-01

Similar Documents

Publication Publication Date Title
CO2024001686A2 (es) Anticuerpos anti-vegfr1 y sus usos
CO2020000214A2 (es) Anticuerpos agonistas que se unen a cd137 humano y sus usos
CL2024001462A1 (es) Proteínas que comprenden dominios de unión al antígeno de la peptidasa 2 relacionada con la calicreína y sus usos.
MX2019015021A (es) Metodo de fabricacion de anticuerpos biespecificos, anticuerpos biespecificos y uso terapeutico de dichos anticuerpos.
AR106570A1 (es) Anticuerpos anti-psma, moléculas de unión al antígeno biespecíficas que se unen a psma y cd3, y usos de estos
MX2017015041A (es) Anticuerpos contra el miembro 4 de la superfamilia del receptor del factor de necrosis tumoral (ox40) y sus usos.
SA522432917B1 (ar) ميوتينات إنترليوكين-21 وطرق العلاج
ECSP22096235A (es) Proteínas que comprenden dominios de unión al antígeno de cd3 y usos de estas
PE20211660A1 (es) Neoantigenos prostaticos y sus usos
MX2018000505A (es) Anticuerpos especificos para tau hiperfosforilada y metodos de uso de los mismos.
MX2023011121A (es) Anticuerpos anti antigeno leucocito 37 (cd37) biespecificos, anticuerpos anti antigeno leucocito 37 (cd37) monoclonales y metodos de uso de los mismos.
PE20240727A1 (es) Anticuerpos anti-psma y usos de estos
MX2017012679A (es) Polipeptidos que contienen dominios de union de novo y usos de los mismos.
MX2019000476A (es) Anticuerpos especificos para la tau hiperfosforilada y sus metodos de uso.
CO2023012586A2 (es) Proteínas que comprenden dominios de unión al antígeno de cd3 y usos de estas
ECSP20039728A (es) Anticuerpos monoclonales y métodos para utilizar los mismos
CL2023001377A1 (es) Anticuerpos anti-npr1 y usos de los mismos
CL2022000096A1 (es) Anticuerpos anti-tigit y aplicación de los mismos
PE20231203A1 (es) Anticuerpos de cadena pesada que se unen al receptor de folato alfa
MX2021000783A (es) Anticuerpos humanizados contra psma.
UY39912A (es) Radioconjugados anti-psma y usos de estos
CL2020001334A1 (es) Anticuerpos que se unen a la proteína de envoltura del virus zika y usos de los mismos. (divisional solicitud 201900999)
CO2023009279A2 (es) Moléculas de unión a gucy2c y sus usos
CL2025000297A1 (es) Anticuerpos anti-ccr8 y métodos de uso
MX2018006250A (es) Biomarcador de enfermedad poliquistica renal y usos del mismo.